• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed by Brainstorm Cell Therapeutics Inc.

    2/14/22 4:05:35 PM ET
    $BCLI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $BCLI alert in real time by email
    SC 13G 1 tm226053d1_sc13g.htm SC 13G

     

     

     

    UNITED STATES 

    SECURITIES AND EXCHANGE COMMISSION 

    Washington, D.C. 20549

     

    SCHEDULE 13G

     

    Under the Securities Exchange Act of 1934 

    (Amendment No. )*

     

    Brainstorm Cell Therapeutics Inc. 

    (Name of Issuer)

     

    Common Stock, $0.00005 par value per share 

    (Title of Class of Securities)

     

    10501E201 

    (CUSIP Number)

     

    Jared Kelly, Esq. 

    Lowenstein Sandler LLP 

    1251 Avenue of the Americas 

    New York 10020 

    (212) 262-6700 

    (Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)

     

    February 14, 2022 

    (Date of Event which Requires Filing of this Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    ¨ Rule 13d-1(b)

     

    x Rule 13d-1(c)

     

    ¨ Rule 13d-1(d)

     

    * The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

     

    The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

     

     

    CUSIP No. 10501E201

     

    1.  

    NAMES OF REPORTING PERSONS

    Abbhi Investments, LLC

    2.  

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (see instructions)

    (a) ¨ (b) ¨

    3.   SEC USE ONLY
    4.  

    CITIZENSHIP OR PLACE OF ORGANIZATION

    Florida

    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

      5.  

    SOLE VOTING POWER

    2,425,853*

      6.  

    SHARED VOTING POWER

    0

      7.  

    SOLE DISPOSITIVE POWER

    2,425,853*

      8.  

    SHARED DISPOSITIVE POWER

    0

    9.  

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    2,425,853*

    10.  

    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (see instructions)

    ¨

    11.  

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    6.69%

    12.  

    TYPE OF REPORTING PERSON (see instructions)

    OO

     

    * Includes 250,000 shares of common stock issuable upon the exercise of warrants, which are exercisable within 60 days at an exercise price of $15.00.

     

     

     

    CUSIP No. 10501E201

     

    1.  

    NAMES OF REPORTING PERSONS

    Sankesh Abbhi (1)

    2.  

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (see instructions)

    (a) o (b) o

    3.   SEC USE ONLY
    4.  

    CITIZENSHIP OR PLACE OF ORGANIZATION

    Florida

    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

      5.  

    SOLE VOTING POWER

    2,425,853*

      6.  

    SHARED VOTING POWER

    0

      7.  

    SOLE DISPOSITIVE POWER

    2,425,853*

      8.  

    SHARED DISPOSITIVE POWER

    0

    9.  

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    2,425,853*

    10.  

    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (see instructions)

    o

    11.  

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    6.69%

    12.  

    TYPE OF REPORTING PERSON (see instructions)

    IN

     

    * Includes 250,000 shares of common stock issuable upon the exercise of warrants, which are exercisable within 60 days at an exercise price of $15.00.

     

    (1) As the manager of Abbhi Investments, LLC who maintains sole voting and investment power with respect to the common stock held by Abbhi Investments, LLC.

     

     

     

    Explanatory Note

     

    This Schedule 13G is filed to report the Reporting Persons’ beneficial ownership of 2,425,853 shares of common stock, $0.00005 par value per share of Brainstorm Cell Therapeutics Inc. (the “common stock”), which includes 250,000 shares of common stock issuable upon the exercise of warrants that are exercisable within 60 days at an exercise price of $15.00. The Reporting Persons’ current beneficial ownership of the common stock is set forth on the cover pages hereto.

     

    Item 1. (a) Name of Issuer:  
           
        Brainstorm Cell Therapeutics Inc. (the “Issuer”)  
           
      (b) Address of Issuer’s Principal Executive Offices:  
           
        1325 Avenue of Americas, 28th Floor
    New York, New York 10019
     
         
    Item 2.     (a) through (c):  
         
      This Schedule 13G is being filed by and on behalf of Abbhi Investments, LLC and Mr. Sankesh Abbhi (collectively, the “Reporting Persons”). Abbhi Investments, LLC is the record owner of the common stock set forth on the cover pages hereto. Mr. Sankesh Abbhi is the manager of Abbhi Investments, LLC and maintains sole voting and investment power with respect to the common stock held by Abbhi Investments, LLC.  
           
      (a)-(c)Name, Address and Citizenship of Reporting Persons 
        Reporting Person: Abbhi Investments, LLC  
        Address: 3119 Ponce de Leon Blvd, Unit C Coral Gables, FL 33134  
       

    Place of Organization: Florida

     

     
       

    Reporting Person: Mr. Sankesh Abbhi

    Address: 3119 Ponce de Leon Blvd, Unit C Coral Gables, FL 33134

    Place of Residence: Florida

     
           
      (d) Title of Class of Securities  
           
        Common Stock, $0.00005 par value per share.  
           
      (e) CUSIP Number  
           
        10501E201  

     

    Item 3. If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:  
             
      (a) ¨ Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o).  
             
      (b) ¨ Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c).  
             
      (c) ¨ Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c).  
             
      (d) ¨ Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8).  
             
      (e) ¨ An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E);  
             
      (f) ¨ An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F);  
             
      (g) ¨ A parent holding company or control person in accordance with §240.13d-1(b)(1)(ii)(G);  
           
      (h) ¨ A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
           
      (i) ¨ A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
           
      (j) ¨ Group, in accordance with §240.13d-1(b)(1)(ii)(J).
               

       

    Not applicable.

     

     

     

    Item 4. Ownership.
       
      Reference is made as to the Reporting Persons’ ownership hereunder to the cover pages of this Schedule 13G, which is incorporated by reference herein. The percentages used herein are calculated based upon 36,277,953 shares of common stock outstanding as of November 15, 2021, as reported by the Issuer in its Form 10-Q filed with the SEC on November 15, 2021.

     

    Item 5. Ownership of Five Percent or Less of a Class.
       
      Not applicable. 

     

    Item 6. Ownership of More than Five Percent on Behalf of Another Person.
       
      Not applicable.

     

    Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company.
       
      Not applicable.

     

    Item 8. Identification and Classification of Members of the Group.
       
      Not applicable.

     

    Item 9. Notice of Dissolution of Group.
       
     

    Not applicable. 

     

    Item 10. Certification.
       
     

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11. 

     

     

     

     

    SIGNATURES

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    Date: February 14, 2022ABBHI INVESTMENTS, LLC
         
    /s/ Sankesh Abbhi
      Name: Sankesh Abbhi
      Title: Manager
         
      SANKESH ABBHI
         
      /s/ Sankesh Abbhi
      Name: Sankesh Abbhi

     

     

     

     

    Exhibit Index

     

    Exhibit1. Joint Filing Agreement as required by Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended.

     

     

     

     

     

     

     

     

    Get the next $BCLI alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $BCLI

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $BCLI
    Financials

    Live finance-specific insights

    See more
    • BrainStorm Receives FDA Clearance to Initiate Phase 3b Trial of NurOwn® for ALS

      Investor call and webcast scheduled for today at 8:30 a.m. ET NEW YORK, May 19, 2025 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ:BCLI), a leading developer of adult stem cell therapies for neurodegenerative diseases, today announced that the U.S. Food and Drug Administration (FDA) has cleared the company to initiate its Phase 3b clinical trial of NurOwn® (autologous MSC-NTF cells) for the treatment of amyotrophic lateral sclerosis (ALS).  The trial design was previously agreed upon with the FDA under a Special Protocol Assessment (SPA), confirming the study's endpoints and statistical methodology are appropriate to support a future Biologics License Application (BLA) submissio

      5/19/25 7:00:00 AM ET
      $BCLI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • BrainStorm Cell Therapeutics Announces First Quarter 2025 Financial Results and Provides Corporate Update

      Conference call and webcast rescheduled for 8:30 a.m. Eastern Time on Monday, May 19 NEW YORK, May 15, 2025 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ:BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today announced financial results for the first quarter ended March 31, 2025, and provided a corporate update. "BrainStorm continues to make meaningful progress in advancing our NurOwn® development program. Our priority continues to be initiation of a Phase 3b trial, designed to confirm the product's efficacy in early stage ALS patients and support a new BLA," said Chaim Lebovits, President and Chief Executive Officer of BrainStorm. "We h

      5/15/25 4:05:00 PM ET
      $BCLI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • BrainStorm Reschedules First Quarter 2025 Financial Results Release to Post-Market Close Today and Sets Investor Call for Monday, May 19

      NEW YORK, May 15, 2025 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ:BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today announced that it has rescheduled the release of its financial results for the first quarter ended March 31, 2025, to post-market close today, May 15. In addition, the Company has rescheduled its previously announced investor conference call, which will now take place on Monday, May 19, 2025, at 8:30 a.m. Eastern Time. BrainStorm's President & Chief Executive Officer, Chaim Lebovits, will present a corporate update to be followed by Q&A. Joining Mr. Lebovits to answer investment community questions will be Haro Hart

      5/15/25 7:30:00 AM ET
      $BCLI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $BCLI
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by Brainstorm Cell Therapeutics Inc.

      SC 13G - BRAINSTORM CELL THERAPEUTICS INC. (0001137883) (Subject)

      11/14/24 3:24:53 PM ET
      $BCLI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G filed by Brainstorm Cell Therapeutics Inc.

      SC 13G - BRAINSTORM CELL THERAPEUTICS INC. (0001137883) (Subject)

      11/13/24 7:55:51 AM ET
      $BCLI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G/A filed by Brainstorm Cell Therapeutics Inc. (Amendment)

      SC 13G/A - BRAINSTORM CELL THERAPEUTICS INC. (0001137883) (Subject)

      2/12/24 10:06:24 AM ET
      $BCLI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $BCLI
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • President & CEO Lebovits Chaim bought $11,308 worth of shares (23,836 units at $0.47), decreasing direct ownership by 93% to 80,960 units (SEC Form 4)

      4 - BRAINSTORM CELL THERAPEUTICS INC. (0001137883) (Issuer)

      10/2/24 8:00:14 AM ET
      $BCLI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: President & CEO Lebovits Chaim bought $7,774 worth of shares (15,000 units at $0.52), increasing direct ownership by 1% to 1,164,865 units (SEC Form 4)

      4/A - BRAINSTORM CELL THERAPEUTICS INC. (0001137883) (Issuer)

      7/31/24 4:09:00 PM ET
      $BCLI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: President & CEO Lebovits Chaim bought $30,475 worth of shares (50,000 units at $0.61), increasing direct ownership by 5% to 1,149,865 units (SEC Form 4)

      4/A - BRAINSTORM CELL THERAPEUTICS INC. (0001137883) (Issuer)

      7/31/24 4:08:32 PM ET
      $BCLI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $BCLI
    SEC Filings

    See more

    $BCLI
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more

    $BCLI
    Leadership Updates

    Live Leadership Updates

    See more
    • Brainstorm Cell Therapeutics Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

      8-K - BRAINSTORM CELL THERAPEUTICS INC. (0001137883) (Filer)

      5/19/25 4:10:20 PM ET
      $BCLI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form DEFA14A filed by Brainstorm Cell Therapeutics Inc.

      DEFA14A - BRAINSTORM CELL THERAPEUTICS INC. (0001137883) (Filer)

      5/16/25 7:05:15 AM ET
      $BCLI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form DEF 14A filed by Brainstorm Cell Therapeutics Inc.

      DEF 14A - BRAINSTORM CELL THERAPEUTICS INC. (0001137883) (Filer)

      5/16/25 7:00:31 AM ET
      $BCLI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Brainstorm Cell upgraded by Maxim Group

      Maxim Group upgraded Brainstorm Cell from Hold to Buy

      2/5/21 8:55:41 AM ET
      $BCLI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Brainstorm Cell Therapeutics upgraded by Maxim Group with a new price target

      Maxim Group upgraded Brainstorm Cell Therapeutics from Hold to Buy and set a new price target of $12.00

      2/4/21 1:51:23 PM ET
      $BCLI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • BrainStorm Cell Therapeutics Announces Appointment of Haro Hartounian Ph.D. as Chief Operating Officer

      Appointment Completes Executive Readiness for Registrational Phase 3b ALS Study Launch NEW YORK, June 20, 2024 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ:BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today announced the appointment of Hartoun Hartounian Ph.D. as its new EVP and COO, effective as of June 18, 2024.     Dr. Hartounian brings a distinguished track record with over 32 years of experience in the biopharmaceutical industry, with a focus on cell and gene therapy. His career highlights include founding and leading BioCentriq, a state-of-the-art cell and gene therapy CDMO facility, which was successfully acquired for $73 mil

      6/20/24 6:00:00 AM ET
      $BCLI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • BrainStorm Cell Therapeutics Appoints Bob Dagher, M.D., as Executive Vice President and Chief Development Officer

      Dr. Dagher has extensive biopharma industry expertise in the development and approval of treatments for challenging neurological and rare diseases NEW YORK, July 12, 2023 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ:BCLI), a leading developer of cellular therapies for neurodegenerative diseases, today announced the appointment of Bob Dagher, MD, as Executive Vice President and Chief Development Officer effective July 17, 2023. Dr. Dagher will serve on BrainStorm's executive leadership team reporting to Stacy Lindborg, Ph.D., co-CEO of BrainStorm.  He will be responsible for the portfolio strategy and advancement of clinical development plans towards regulatory approval, includin

      7/12/23 7:00:00 AM ET
      $BCLI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • BrainStorm Cell Therapeutics Appoints Nir Naor as Board Member and Audit Committee Chair

      NEW YORK, June 20, 2023 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ:BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today announced the appointment of Nir Naor, CPA, CFA, MBA (IMD), LL.M, as Board Member, chairman of its Audit Committee and member of its Governance, Nomination and Compensation Committee (GNC), effective June 20. Mr. Naor is replacing Mr. Malcolm Taub, who will retire from the same roles after 14 years of service on the Company's board of directors. "We welcome the addition of Nir as a new independent board member, and we are confident that his impressive corporate experience in both the U.S. and Europe will add further

      6/20/23 9:06:00 AM ET
      $BCLI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $BCLI
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • BrainStorm Secures Key Manufacturing Partnership with Minaris for Upcoming NurOwn® Phase 3b ALS Clinical Trials

      NEW YORK, May 27, 2025 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ:BCLI), a leading developer of adult stem cell therapies for neurodegenerative diseases, today announced that it has signed a Letter of Intent (LOI) with Minaris Advanced Therapies, a global contract development and manufacturing organization (CDMO) specializing in cell and gene therapies, to manufacture NurOwn® for its upcoming clinical trial. The LOI marks the beginning of a strategic collaboration between BrainStorm and Minaris to initiate the technology transfer of NurOwn® in preparation for clinical trial manufacturing at Minaris' state-of-the-art facility in Allendale, New Jersey. This partnership supports

      5/27/25 7:00:00 AM ET
      $BCLI
      $PLUR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • BrainStorm Receives FDA Clearance to Initiate Phase 3b Trial of NurOwn® for ALS

      Investor call and webcast scheduled for today at 8:30 a.m. ET NEW YORK, May 19, 2025 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ:BCLI), a leading developer of adult stem cell therapies for neurodegenerative diseases, today announced that the U.S. Food and Drug Administration (FDA) has cleared the company to initiate its Phase 3b clinical trial of NurOwn® (autologous MSC-NTF cells) for the treatment of amyotrophic lateral sclerosis (ALS).  The trial design was previously agreed upon with the FDA under a Special Protocol Assessment (SPA), confirming the study's endpoints and statistical methodology are appropriate to support a future Biologics License Application (BLA) submissio

      5/19/25 7:00:00 AM ET
      $BCLI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • BrainStorm Cell Therapeutics Announces First Quarter 2025 Financial Results and Provides Corporate Update

      Conference call and webcast rescheduled for 8:30 a.m. Eastern Time on Monday, May 19 NEW YORK, May 15, 2025 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ:BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today announced financial results for the first quarter ended March 31, 2025, and provided a corporate update. "BrainStorm continues to make meaningful progress in advancing our NurOwn® development program. Our priority continues to be initiation of a Phase 3b trial, designed to confirm the product's efficacy in early stage ALS patients and support a new BLA," said Chaim Lebovits, President and Chief Executive Officer of BrainStorm. "We h

      5/15/25 4:05:00 PM ET
      $BCLI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $BCLI
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Medical Officer Dagher Ibrahim B. was granted 50,000 shares, increasing direct ownership by 297% to 66,849 units (SEC Form 4)

      4 - BRAINSTORM CELL THERAPEUTICS INC. (0001137883) (Issuer)

      1/7/25 4:11:08 PM ET
      $BCLI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: New insider Dagher Ibrahim B. claimed ownership of 505,742 shares (SEC Form 3)

      3/A - BRAINSTORM CELL THERAPEUTICS INC. (0001137883) (Issuer)

      1/7/25 4:10:10 PM ET
      $BCLI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • President & CEO Lebovits Chaim was granted 120,000 shares, increasing direct ownership by 148% to 200,960 units (SEC Form 4)

      4 - BRAINSTORM CELL THERAPEUTICS INC. (0001137883) (Issuer)

      1/3/25 5:36:42 PM ET
      $BCLI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care